Company Overview and News

 
Conifex Announces Third Quarter 2018 Results Conference Call

2018-10-10 globenewswire
VANCOUVER, B.C., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. (“Conifex”) (TSX: CFF) announced today that it plans to release its third quarter 2018 results prior to the market open on Thursday, November 8, 2018. Conifex has scheduled a conference call at 8:00 AM Pacific time / 11:00 AM Eastern time on the same day to discuss its financial results. To participate in the call, please dial one of the following numbers:
CFXTF CFF

 
Update on Conifex Operations at Fort St. James

2018-08-20 globenewswire
VANCOUVER, British Columbia, Aug. 20, 2018 (GLOBE NEWSWIRE) -- The Regional District of Bulkley-Nechako has issued an evacuation alert due to wildfire activity for an area which includes the town of Fort St. James and our mill site. As wildfire conditions continued to deteriorate, Conifex Timber temporarily suspended operations Friday of last week.
CFXTF CFF

 
Conifex Announces Second Quarter 2018 Results Conference Call

2018-07-17 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. (“Conifex”) (TSX:CFF) announced today that it plans to release its second quarter 2018 results prior to the market open on Friday, August 10, 2018. Conifex has scheduled a conference call at 7:00 AM Pacific time / 10:00 AM Eastern time on the same day to discuss its financial results. To participate in the call, please dial one of the following numbers:
CFXTF CFF

 
Conifex Completes Acquisition of Sawmills in the U.S. South

2018-07-09 globenewswire
VANCOUVER, British Columbia, July 09, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. ("Conifex", the "Company", "we", "our" or "us") (TSX:CFF) announced today that it has completed the acquisition of the Suwannee sawmill in Cross City, Florida and the Caddo River sawmill in Glenwood Arkansas.
CFXTF CFF

 
Conifex Announces Voting Results

2018-06-27 globenewswire
VANCOUVER, British Columbia, June 26, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. ("Conifex" or the "Company") (TSX:CFF) is pleased to announce that at its annual general and special meeting held on June 25, 2018 (the "Meeting"), all nominees listed in its management information circular dated May 25, 2018 were elected as directors of the Company.
CFXTF CFF

 
Conifex Announces Closing of Subscription Receipt Offering

2018-06-19 globenewswire
VANCOUVER, British Columbia, June 19, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. ("Conifex" or the "Corporation") (TSX:CFF) is pleased to announce that it has completed its previously announced offering (the "Offering") of subscription receipts (the "Subscription Receipts").
CFXTF CFF

 
Conifex Announces Pricing of Subscription Receipt Offering and Filing of Final Short Form Prospectus

2018-06-12 globenewswire
VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. ("Conifex" or the "Corporation") (TSX:CFF) is pleased to announce that, further to its news release dated May 25, 2018, it is filing a final short form prospectus (the "Prospectus") with applicable Canadian securities regulatory authorities with respect to a marketed offering (the "Offering") of 10,750,000 subscription receipts (the "Subscription Receipts") of the Corporation at a price of $6.
CFXTF CFF

 
Conifex Announces Offering of Subscription Receipts and Filing of Preliminary Short Form Prospectus

2018-05-27 globenewswire
VANCOUVER, British Columbia, May 25, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. ("Conifex" or the "Corporation") (TSX:CFF) is pleased to announce that it has filed a preliminary short form prospectus with applicable Canadian securities regulatory authorities with respect to a marketed offering of the Canadian dollar equivalent of approximately US$50 – US$55 million (the "Offering") of subscription receipts (the "Subscription Receipts") of the Corporation.
CFXTF CFF

 
Conifex Announces First Quarter 2018 Results

2018-05-16 globenewswire
VANCOUVER, B.C., May 15, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. (“Conifex”, "we" or "us") (TSX:CFF) today reported results for the first quarter ended March 31, 2018. EBITDA in the first quarter of 2018 was $9.3 million, compared to $17.5 million in the fourth quarter of 2017 and $6.1 million in the first quarter of 2016. EBITDA included countervailing (“CV”) and anti-dumping (“AD”) duty expense on softwood lumber shipments to the U.
CFXTF CFF

 
Conifex Announces First Quarter 2018 Results Conference Call

2018-04-16 globenewswire
VANCOUVER, British Columbia , April 16, 2018 (GLOBE NEWSWIRE) -- Conifex Timber Inc. (“Conifex”) (TSX:CFF) announced today that it plans to release its first quarter 2018 results prior to the market open on Tuesday, May 15, 2018. Conifex has scheduled a conference call at 8:00 AM Pacific time / 11:00 AM Eastern time on the same day to discuss its financial results. To participate in the call, please dial one of the following numbers:
CFXTF CFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 207324104